Opiant Pharmaceuticals to Hold Virtual 2021 Annual Shareholder Meeting on Tuesday, June 15, 2021 at 9:00am PDT
May 18 2021 - 4:05PM
Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a
specialty pharmaceutical company developing medicines to treat
addictions and drug overdose, announced today that, due to the
continuing public health concerns relating to the coronavirus
(COVID-19) pandemic, and to protect the health and well-being of
its shareholders, employees, and other stakeholders, Opiant's 2021
Annual Meeting of Shareholders will be held in a virtual-only
meeting format via live audio webcast. The original date and time
of the 2021 Annual Meeting, as well as the matters to be voted on
at the 2021 Annual Meeting, remain unchanged.
The Company’s proxy statement describing the formal business to
be conducted at the meeting is available on the Investors section
of the Company’s website at:
https://ir.opiant.com/static-files/90791c5a-5c1e-40df-ab4a-4e54cbb7630f
Shareholders who elect to virtually attend the meeting may do so
as follows:
Date: Tuesday, June 15, 2021Time: 9:00 a.m. (PDT)Live
Virtual Meeting: https://zoom.us/j/91932669149 (Meeting ID:
919 3266 9149)
Live call: 877 369 0926 (US Toll-free) or 877 853 5247 (US
Toll-free) or Find your local number
via https://zoom.us/u/aO3gNgQ4J
Shareholders of record at the close of business on April
16, 2021, the record date for the 2021 Annual Meeting, are entitled
to participate in the virtual meeting and will need their assigned
16-digit control number to vote shares electronically at the
virtual meeting by submitting an email to:
Admin12@astfinancial.com
Important Information for Voting Shares
Your vote is important. Whether or not shareholders plan to
attend the virtual-only annual meeting, Opiant urges shareholders
to vote and submit their proxies in advance of the meeting by one
of the methods described in the proxy materials.
Shareholders of record with Internet access may submit proxies
until 11:59 p.m., Eastern Time, on June 14, 2021, by following the
instructions on your proxy cards or at www.voteproxy.com.
Shareholders who have already voted their shares do not need to
vote them again because of this change in meeting format.
A list of shareholders entitled to vote at the 2021 Annual
Meeting will be available for review by interested shareholders at
the offices of the Company, 233 Wilshire Blvd., Suite
280, Santa Monica, CA 90401, beginning on June 5,
2021. Please contact the Company’s Investor Relations by sending an
e-mail to batkins@opiant.com, if you wish to inspect the list
prior to the meeting.
Attending the Annual Meeting as a Guest
Those without a control number may attend the virtual meeting as
guests, but will not have the option to vote.
About Opiant Pharmaceuticals, Inc.Opiant
Pharmaceuticals, Inc., the company that developed NARCAN® Nasal
Spray, is building a leading franchise of new medicines
to combat addictions and drug overdose.For more information
visit: www.opiant.com.
Forward-Looking StatementsThis press release
contains forward-looking statements. These statements relate to
future events or our future financial performance and involve known
and unknown risks, uncertainties and other factors that may cause
our or our industry's actual results, levels of activity,
performance or achievements to be materially different from any
future results, levels of activity, performance or achievements
expressed, implied or inferred by these forward-looking statements,
and among other things, our ability to maintain cash balances and
successfully commercialize or partner our product candidates
currently under development. In some cases, you can identify
forward-looking statements by terminology such as "may," "will,"
"should," "could," "would," "expects," "plans," "intends,"
"anticipates," "believes," "estimates," "predicts," "projects,"
"potential," or "continue" or the negative of such terms and other
same terminology. These statements are only predictions based on
our current expectations and projections about future events. You
should not place undue reliance on these statements. Actual events
or results may differ materially. In evaluating these statements,
you should specifically consider various factors. Additional
factors that could materially affect actual results can be found in
our filed quarterly reports on Form 10-Q and our annual report on
Form 10-K for the year ended December 31, 2020, filed with
the Securities and Exchange Commission on March 4,
2021, including under the caption titled "Risk Factors." These and
other factors may cause our actual results to differ materially
from any forward-looking statement. We undertake no obligation to
update any of the forward-looking statements after the date of this
press release to conform those statements to reflect the occurrence
of unanticipated events, except as required by applicable
law.Investor Relations Contacts:
Ben AtkinsVP of Corporate Communications and
Investor RelationsBatkins@opiant.com(310) 598-5410
Opiant Pharmaceuticals (NASDAQ:OPNT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Opiant Pharmaceuticals (NASDAQ:OPNT)
Historical Stock Chart
From Apr 2023 to Apr 2024